<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971643</url>
  </required_header>
  <id_info>
    <org_study_id>IFX-1-P2.7</org_study_id>
    <nct_id>NCT03971643</nct_id>
  </id_info>
  <brief_title>Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum</brief_title>
  <official_title>Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InflaRx GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovaderm Research Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InflaRx GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IFX-1 is safe and effective in the&#xD;
      treatment of pyoderma gangrenosum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neutrophilic dermatoses are a spectrum of inflammatory disorders characterized by skin&#xD;
      lesions resulting from a neutrophil-rich inflammatory infiltrate in the absence of infection.&#xD;
      Pyoderma gangrenosum is associated with a neutrophilic leukocytosis, which is likely to be&#xD;
      triggered by C5a. This study is set up based on the hypothesis that IFX-1 might be able to&#xD;
      block C5a induced pro-inflammatory effects such as neutrophil activation and cytokine&#xD;
      generation, potentially contributing to the local skin inflammation and tissue damage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>IV infusions of IFX-1 diluted in sodium chloride</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the safety of IFX-1 for the treatment of subjects with pyoderma gangrenosum: Occurrence, nature and intensity of treatment emergent adverse events (TEAEs), related TEAEs, and serious TEAEs.</measure>
    <time_frame>through study completion, up to 36 weeks</time_frame>
    <description>The endpoints will be the occurrence, nature and intensity of treatment emergent adverse events (TEAEs), related TEAEs, serious TEAEs and adverse events of special interest.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Pyoderma Gangrenosum</condition>
  <arm_group>
    <arm_group_label>IFX-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exploratory, Proof of Concept with a total of 15 doses of IFX-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFX-1</intervention_name>
    <description>IV infusions of IFX-1 diluted in sodium chloride.</description>
    <arm_group_label>IFX-1</arm_group_label>
    <other_name>CaCP29</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an ulcerative form of pyoderma gangrenosum confirmed by the investigator&#xD;
&#xD;
        In addition, the subject must fulfill at least 3 of the following 6 criteria at screening:&#xD;
&#xD;
        History of&#xD;
&#xD;
          -  Pathergy (ulcer occurring at the sites of trauma)&#xD;
&#xD;
          -  Personal history of inflammatory bowel disease or inflammatory arthritis&#xD;
&#xD;
          -  History of papule, pustule or vesicle that rapidly ulcerated&#xD;
&#xD;
        Clinical examination (or photographic evidence) of&#xD;
&#xD;
          -  Peripheral erythema, undermining border, and tenderness at site of ulceration&#xD;
&#xD;
          -  Multiple ulcerations (at least 1 occurring on the lower leg)&#xD;
&#xD;
          -  Cribriform or &quot;wrinkled paper&quot; scar(s) at sites of healed ulcers&#xD;
&#xD;
        Subject has a minimum of 1 evaluable ulcer (≥2 cm2) on the lower extremity at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pyoderma gangrenosum target ulcer for more than 3 years before screening&#xD;
&#xD;
          -  Surgical wound debridement within the previous 2 weeks before screening&#xD;
&#xD;
          -  Use of intravenous antibacterials, antivirals, anti-fungals, or anti-parasitic agents&#xD;
             within 30 days before screening&#xD;
&#xD;
          -  Any drug treatment for pyoderma gangrenosum including corticosteroids (&gt;10 mg),&#xD;
             intralesional steroids, cyclosporine A, biologicals and immunosuppressives (with the&#xD;
             exception of antibiotics for wound superinfection) used within a time of 5 half-lives&#xD;
             of the drug before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Korinna Pilz, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>InflaRx GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Korinna Pilz, MD, MSc</last_name>
    <phone>+49 89 4141 8978 97</phone>
    <email>info@inflarx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>InflaRx Site #07</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #08</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #03</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #10</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #05</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #06</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #09</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #04</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #01</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #02</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #21</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InflaRx Site #20</name>
      <address>
        <city>Wrocław</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vilobelimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

